Compare NTWK & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTWK | RANI |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.8M | 84.6M |
| IPO Year | 1997 | 2021 |
| Metric | NTWK | RANI |
|---|---|---|
| Price | $4.30 | $0.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 179.6K | ★ 476.8K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $78,145,875.00 | $1,633,000.00 |
| Revenue This Year | $14.51 | $317.02 |
| Revenue Next Year | $9.99 | N/A |
| P/E Ratio | $436.00 | ★ N/A |
| Revenue Growth | 6.92 | ★ 58.85 |
| 52 Week Low | $2.80 | $0.50 |
| 52 Week High | $8.46 | $1.91 |
| Indicator | NTWK | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 29.14 | 42.85 |
| Support Level | $4.20 | $0.51 |
| Resistance Level | $4.65 | $0.85 |
| Average True Range (ATR) | 0.63 | 0.04 |
| MACD | -0.42 | 0.01 |
| Stochastic Oscillator | 5.10 | 58.08 |
NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.